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Duchenne muscular dystrophy (DMD), the most common form of muscular dystrophy, is characterized by muscular wasting
caused by dystrophin deficiency that ultimately ends in force reduction and premature death. In addition to primary genetic
defect, several mechanisms contribute to DMD pathogenesis. Recently, antioxidant supplementation was shown to be effective
in the treatment of multiple diseases including muscular dystrophy. Different mechanisms were hypothesized such as reduced
hydroxyl radicals, nuclear factor-𝜅B deactivation, and NO protection from inactivation. Following these promising evidences, we
investigated the effect of the administration of a mix of dietary natural polyphenols (ProAbe) on dystrophic mdx mice in terms
of muscular architecture and functionality. We observed a reduction of muscle fibrosis deposition and myofiber necrosis together
with an amelioration of vascularization.More importantly, the recovery of themorphological features of dystrophic muscle leads to
an improvement of the endurance of treated dystrophic mice. Our data confirmed that ProAbe-based diet may represent a strategy
to coadjuvate the treatment of DMD.
1. Introduction
Muscular dystrophies (MDs) are a heterogeneous group of
disorders characterized by muscular wasting and inflamma-
tion that ultimately cause reduction of force and premature
death [1]. The role of inflammatory cells is not completely
understood but it is known that they could exacerbate
muscular wasting, either directly or by secreting media-
tors, like cytokines and complement’s component [2], and
by reactive oxygen species (ROS) production [3–5]. ROS
were shown to increase membrane permeability in muscle
fibres, most likely through lipid peroxidation [6]. Different
groups demonstrated that increased ROS production was
a primary feature of dystrophic muscle damage and not
simply a consequence ofmuscular degeneration [7, 8]. Others
showed that ROS-mediated effect on dystrophic muscles
increased protein oxidation, which could cause a wide range
of deleterious effects on muscle contractile function [9], both
in mdx mice [10] and in DMD patients [11]. It is now known
that the intracellular increase in ROS formation typical of
the pathological conditions of the MDs is mainly due to
mitochondria [12]. Even if the precise mechanism by which
oxidative stress causes mitochondria dysfunction is not clear,
numerous studies reported that ROS could negativelymodify
both expression and structural conformation of the proteins
that are involved in normal mitochondria functions [13, 14].
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In latest years, antioxidant supplementationwas shown to
be useful in the treatment of different diseases like atheroscle-
rosis, autoimmunitary diseases, diabetes, and chronic dis-
eases including muscular dystrophies [15–18]. The beneficial
effects of antioxidants were correlated with their ability to
reduce oxidative stress, deactivate nuclear factor-𝜅B (NF-
𝜅B) pathway, and vascular effects like vasodilatation and
antihypertension through NOS pathway [19]. Many natural
antioxidants were tested in animal model of muscular dys-
trophies and these studies reported amelioration in muscle
morphology and function [20].
As an example, green tea is rich in antioxidants such
as catechins and also in minerals and vitamins so that
it was demonstrated to be useful in the reduction of the
risk of cardiovascular diseases and of fibrosis development
[21]. Interestingly, in vivo studies on mdx mice fed with
antioxidants derived from green tea showed reduced signs
of muscular damage and ameliorated hydroxyl radicals
content, oxidative stress, and fibrosis in treated muscles
[22]. According to the emerging role of vitamins in the
prevention of chronic diseases [23], Murphy and Kehrer
observed similarities between the development of patho-
logical signs in muscular dystrophies and the pathology of
muscles exposed to oxidative stress in vitamin E deficiency
[24]. Messina and coworkers demonstrated that a synthetic
vitamin E analogue, IRFI-042, possessing strong antioxidant
properties, improved mdx muscle function and reduced the
activation of NF-𝜅B [25]. NF-𝜅B is a key regulator of several
genes such as the proinflammatory cytokine TNF-𝛼 [26]
and matrix metalloproteinases [27]. In this sense, Kumar
and Boriek showed that passive stretch of mdx diaphragm
increased activation of NF-𝜅B, which was attenuated by
the antioxidant N-acetylcysteine [28]. At the same time, it
was demonstrated that systemic administration of the NF-
𝜅B inhibitor curcumin stimulated muscle regeneration after
traumatic injury, suggesting a beneficial effect of curcumin
supplementation in alleviating dystrophic signs [29]. A pos-
sible role for coenzyme Q10 (CoQ10) in the development of
different diseases was investigated: especially in cardiovascu-
lar pathologies, relatively low levels of CoQ10 were assessed
in myocardial tissue [30]. More recently, CoQ10 was added
to prednisone therapy in DMD patients, increasing muscle
strength [31]. Similarly, carnitine held much promise in
neural disorders, allowing osmoprotection and modulating
immune and inflammatory responses [32]. Several works
showed that this compound regulated lipid metabolism in
DMD patients, restoring muscle membrane fluidity [33],
decreasing glucose oxidation, and reducing fatty acid [34].
Following previously published data [35], Fogagnolo and
colleagues demonstrated that mdx mice fed with docosahex-
aenoic acid (DHA) decreased plasma creatine kinase levels
and myonecrosis, reducing inflammatory area and the levels
of TNF-𝛼 [36]. In the end, another natural flavonoid, the
baicalein, was used as a potent anti-inflammatory agent to
diminish the concentration of free radicals [37, 38].
Palomero et al. showed that muscular fibres during
exercise produce ROS [39]. Interestingly, Reid et al. proposed
a correlation between ROS levels and force production. They
showed that the maximum force was achieved by unfatigued
skeletal muscle when exposed to low levels of oxidants. As
either an increase or a reduction in ROS levels determined a
reduction in muscle force, they suggested that there was an
optimal redox state for force production [40]. Reid proposed
that ROS could affect muscle force production by oxidation
of contractile and excitation-contraction (E-C) coupling
proteins [41] and the role of ROS in mediating muscle
fatigue was demonstrated by treatment with antioxidants
[42, 43]. Recently Renjini et al. showed that oxidative damage
in muscular dystrophy correlates with the severity of the
pathology [44] while Selsby and collaborators proved that the
overexpression of the antioxidant enzyme catalase improved
muscle function in the mdx mouse, especially the resistance
to fatigue [45]. Following these promising evidences, several
clinical trials started using antioxidants in DMD patients.
However, the results were disappointing due to a number of
factors, which could account for the negative outcome [7].
First of all, DMD patients were chosen at an advanced stage
of the disease, when significant muscle fibre loss had already
occurred. Unfortunately, antioxidants would be expected to
either reduce or preventmuscle damage and degeneration but
not to replace lost fibres. Moreover, the antioxidants used in
these trials—such as superoxide dismutase (SOD), vitamin E,
and selenium—were notmembrane-permeant andwere inef-
fective in scavenging intracellular ROS [20]. Furthermore,
several works demonstrated that the combination of different
polyphenols might enhance their therapeutic effects, due to a
synergic effect of different antioxidants or the contemporary
targeting of multiple pathologic pathways [17, 46–48].
According to these evidences, we fed mdx mice with a
mix of natural polyphenols (ProAbe), constituted by a liquid
phase and a solid phase and we evaluated the amelioration
of muscle histology, the oxidation damage, and the possi-
ble increase of muscle mass and endurance in dystrophic
background. Our data confirmed that the treatment with
antioxidants could open a new era in treating muscular
diseases.
2. Results
2.1.Muscular Features ofmdxMice. Fibrosis is considered the
most devastating consequence of the progression of disease in
DMDpatients: due to the lack of dystrophin, satellite cell pro-
liferation cannot compensate constant myofiber breakdown
so that inflammatory processes that followmuscular necrosis
lead to fibrotic remodelling and finally fatty cell replacement.
As in DMD children, the muscle pathology progressed in
mdx mice as a function of age. This way, we fed 3-month-
old mdx mice (𝑛 = 5) with ProAbe and we performed H&E
analysis of muscle sections to verify whether this diet could
delay the onset of the pathology. In tibialis anterior (TA) and
quadriceps (QA) of treated mice, we observed the presence
of degenerating and small centrally nucleated regenerating
muscle fibers, such as in untreated mice; however reduced
signs of degeneration (consisting in hypertrophic fibers, fiber
splitting, and fat replacement) were seen in treated mice
versus untreated ones (𝑛 = 5) (Figure 1(a)). To verify
whether antioxidants supplementation could bear an effect
on muscle mass we measured cross-section fiber area (CSA)
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Figure 1: Continued.
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Figure 1: H&E analysis of treated and untreatedmice. H&E staining was performed on 10𝜇m-thick frozen sections fromTA andQAmuscles
(a). In treated mice reduced signs of muscular wasting were observed in comparison to untreated mice. In particular reduced inflammatory
infiltrates between myofibers, reduced fat deposition, and reduced necrotic fibers were assessed. In both treated and untreated mice small
centronucleated regenerating fibers were observed. For each muscle analyzed with H&E staining we showed the myofiber area and their
distribution frequency (b). The curve of TA/QAmuscles of treated mice shifted to the right related to untreated mice, thus demonstrating an
increase inmyofiber area of treatedmice (CSAQA: 25∘ percentile of treatedmice 1221,26 and of untreatedmice 903,152; CSATA: 25∘ percentile
of treatedmice 1120,39 and of untreatedmice 874,068; CSAQA: 75∘ percentile of treatedmice 3107,04 and of untreatedmice 1946,06; and CSA
TA: 75∘ percentile of treated mice 2978,59 and of untreated mice 1883,39). Moreover, we indicated the coefficient of variance (graphs showing
Min and Max values and mean + SEM) ((c) for QA and (d) for TA). Amelioration of dystrophic phenotype following ProAbe treatment was
demonstrated by decrease of fibrosis by measuring area of connective tissue (AM) (e), of the percentage of necrotic fibers (f), of macrophage
infiltration area (CD11b staining) (g), and of the number of centronucleated myofibers per section (h).
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of both treated and untreated mdx mice. We found that
the distribution curves of treated mice shifted to the right
in comparison to that one related to mdx control group,
thus proving that there was a significant increase in fiber
CSA in both muscles examined (TA and QA muscles) (F
test to compare variance was significant for 𝑃 < 0,0001)
(Figures 1(b)–1(d)). In particular there was a reduction in
the percentage of smaller fibers (CSA of QA in treated
2274 ± 32,59 and untreated mice 1535 ± 20,08; CSA of
TA in treated 1681 ± 23,76 and untreated mice 1486 ±
19,44; t-test to compare mean was significant for 𝑃 <
0,0001) (Figures 1(c)-1(d)). To better elucidate that ProAbe-
dependent increase of muscle size was not due to fibrotic
deposition, other morphological features of the muscles of
treated mice were measured. We demonstrated a diminished
percentage of fibrosis in both muscles treated with ProAbe
(treated QA 6,255 ± 0,632 and untreated QA 14,67 ± 0,66
𝑃 < 0,0001; treated TA 11,29 ± 0,736 and untreated TA
20,62 ± 1,521 𝑃 < 0.0001) (Figure 1(e)) and we observed that
the percentage of necrotic fibers was significantly smaller in
both treatedmuscles (treated QA 0,8944±0,06 and untreated
QA 2,015 ± 0,376, 𝑃 = 0,045; treated TA 3,867 ± 0,4884
and untreated TA 11,35 ± 1,926, 𝑃 = 0,0093) (Figure 1(f)).
As clearly described by different works [49–51] inflammatory
cells in DMD can interact with resident muscular stem
cells and cause the fibroadipogenic degeneration of muscular
fibers. According to these evidences, CD11b staining was
performed to identify macrophage infiltrates as an indicator
of muscle inflammation and we assessed a reduction in
inflammatory infiltrates both in TA and in QA muscles of
treated mice (untreated TA: 21130 ± 4909 and treated TA:
6187 ± 1460, 𝑃 = 0,0154; untreated QA 24610 ± 2217 and
treatedQA 10080±1559,𝑃 = 0,0017) (Figure 1(g)).Moreover,
we counted the number of centronucleated myofibers—that
are the fibers in regeneration—and we demonstrated that
their number was smaller in both treated muscles (untreated
TA: 39,79 ± 4,571 and treated TA: 23,64 ± 2,833; 𝑃 = 0,0133;
untreated QA 40,42 ± 8,645 and treated QA 18,05 ± 3,981,
𝑃 = 0,0369) (Figure 1(h)).
2.2. ForceMeasurement. To verifywhether a natural polyphe-
nols diet could improve muscular functionality we first test
the endurance of treated and untreated mdx mice (𝑛 =
10 per each group). In these experiments we found that
ProAbe administration significantly increased the endurance
ability of mdx mice after 4 weeks of treatment (total average
hours run: mdx treated 3,656 ± 0,728 versus mdx untreated
1,844 ± 0,426; 𝑃 = 0,0474) (Figure 2(a)). We measured
the total motor capacity relative to baseline performance
and we observed an increase of 30% at day 30 of treatment
(Figure 2(b)). Dystrophic animals assessed at 30 days of treat-
ment showed an increased tolerance to exercise as demon-
strated by the time to exhaustion (mdx treated 14,33 ± 0,817
versus mdx untreated 11,02 ± 0,849; 𝑃 = 0,0117) (Figure 2(c)).
Furthermore, we calculated the tetanic force of TA and DIA
of treated and untreated mdx (𝑛 = 5 per each group) and
we found a minimum but not significant improvement of the
values in treated mdx muscles (Figures 2(d) and 2(e)).
2.3. Oxidative State Evaluation. To evaluate whether natural
polyphenols diet could influence ROS production we quan-
tified dihydroethidium (DHE) staining in muscle sections
from treated and untreated dystrophic mdx mice (𝑛 = 5 per
each group). DHE oxidation by intracellular ROS causes the
formation of ethidium bromide, which fluoresces red, once
intercalated within DNA.Thus nuclear fluorescence intensity
directly correlates with ROS production. We measured DHE
fluorescence intensity on sections of TA andQA (Figure 3(a))
and we found that the ProAbe-enriched diet significantly
diminished ROS production (TA of treated 68450±7782 and
untreated mdxmice 95470±5185; 𝑃 = 0,0277) (Figure 3(b)).
In QAmuscle of treated mice we observed a similar decrease
in ROS production that did not reach statistical significance
(QA of treated 82940 ± 3434 and untreated mdx mice
95330 ± 5219; 𝑃 = 0,1183). C57Bl mice were used as control
(42380 ± 1378). As shown in Figure 3(a), DHE stained both
myofiber nuclei and cell infiltrates: after ProAbe treatment,
DHE staining was reduced both in inflammatory infiltrates
and in myofiber nuclei (Figure 3(a)). To determine whether
the reduction in DHE intensity was related to reduced
inflammatory infiltrates (as previously shown in Figure 1(g)),
we correlated both data and we showed that the reduction of
inflammatory infiltrates was major than the corresponding
reduction of DHE intensity (Figure 3(c)). As the number of
myofiber nuclei was equivalent, ProAbe treatment influenced
more the ROSproduced bymyofibers than those produced by
infiltrating cells in particular macrophages.
2.4. Mitochondria. As cited before, we determined whether
the effects of ProAbe on ROS production were exerted on
mitochondria and we evaluated the activity of mitochon-
drial enzymes in QA and diaphragm (DIA) of treated and
untreated C57Bl (𝑛 = 5) and mdx mice (𝑛 = 5) (Figure 4).
Wedemonstrated that therewere no significantmodifications
within the activity of these enzymes in treated mice.
2.5. Vascular Features. To test the influence of antioxidants
upon muscle vascular architecture, we performed CD31+, 𝛼-
sma, and laminin immunofluorescence staining on muscle
sections from TA and QA of treated and untreated mice
(𝑛 = 5) (Figure 5(a)). We counted the number of CD31+
vessels per fiber (capillaries) and of 𝛼-sma+ vessels per fiber
(arterioles). The increase of CD31+ vessels in treated muscles
was statistically significant in dystrophic mice (TA mdx
treated versus TAmdx untreated: 1,553± 0,059 versus 1,272±
0,045; 𝑃 < 0,001), but it was not significant in normal mice
(TA C57Bl treated versus TA C57Bl untreated: 3,146 ± 0,1076
versus 2,835 ± 0,1289; 𝑃 = 0,0624) (Figure 5(b)). Therefore,
we found that all treated mice had a significant increase in
𝛼-sma+ vessels per fiber (TA mdx treated versus TA mdx
untreated: 7,85± 0,2975 versus 3,233± 0,2108; 𝑃 < 0,0001; TA
C57Bl treated versus TA C57Bl untreated: 6,04 ± 0,34 versus
3,54±0,2;𝑃 < 0,0001), thus demonstrating an amelioration of
muscle perfusion (Figure 5(c)). QA muscles had similar but
less significant amelioration of vascular compartment (data
not shown).
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Figure 2: Endurance test. Histogram representing endurance test of treated mice. (a) Each symbol corresponds to a single animal
performance; endurance test was repeated once per day for 30 days for each mouse. The average value corresponds to the total amount
of time measured during the tests for 30 days. As demonstrated by the average number of hours run mdx-treated mice increased significantly
their performance versus untreated mice, even if this value was far from that of C57Bl mice (a). (b) Graph showed relative motor capacity
of mice (percentage normalized to baseline) at 4 different time points (each week for 30 days). (c) Graph showed the absolute value of T4 of
graph in (b) (that is the average time to exhaustion at T4 (30 days)) that was higher in mdx treated mice related to untreated ones. Tetanic
force of TA (d) and DIA (e) was performed in treated and untreated mdx mice.
2.6. Stem Cell Mobilization Mediated by ProAbe Treatment.
To test the hypothesis that ProAbe could favour the mobil-
isation of bone marrow stem cells as demonstrated for other
natural components [52–54], we collected the blood from
C57Bl and mdx mice fed with ProAbe at different time
points (𝑛 = 5 for each strain) and we investigated the
expression of different cellular markers by FACS analysis. T0
(before treatment) was used as baseline. We chose CD34, a
cell-cell adhesion factor, able to mediate the attachment of
stem cells to bone marrow extracellular matrix; CXCR4 that
regulates the mobilization of haematopoietic stem cells into
the bloodstream as peripheral blood stem cells; and Sca-1 that
is a classical stem cell antigen. Following the treatment with
ProAbe, we observed a mobilization of stem cells from bone
barrow to the peripheral blood (7-fold increase in peripheral
CD34+ stem cells at 24 h of treatment related to baseline)
and we assessed that the mobilization in the dystrophic mice
was higher related to C57Bl mice. Values were normalized on
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Figure 3: DHE staining and quantification. (a) DHE staining onmuscle sections from TA andQA ofmdxmice. DHE staining revealed anion
superoxide production at nuclear level. Arrows indicated DHE staining on both cellular infiltrate and fibers myonuclei. (b) We quantified
DHE staining intensity on muscle section. Histogram showed a reduced production of oxidative damage as measured by DHE staining in TA
muscle of mdx-treated mice versus untreated ones (𝑃 < 0,05). (c) Graph showed the correlation between DHE staining intensity and CD11b+
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(as shown by right position of untreated mice versus left position of treated mice).
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Figure 4: Enzymatic activity ofmitochondrial enzymes.Histogram representing enzymatic activity of a wide range ofmitochondrial enzymes
involved in respiratory chain complexes. No significant differences were evidenced between treated or untreated mdx mice in DIA and QA.
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C reductase/citrate synthase; and succinate cit C red/citr sint: succinate citrate C reductase/citrate synthase).
the total number of CD45+ stem cells and the significance of
these values was related to the T0 (before treatment) value
(% of CD34+ in mdx: T0: 0,8775±0,2893; T24: 4,684±0,6313
with 𝑃 = 0,028; T72 h: 8,717 ± 2,309 with 𝑃 = 0,0104. %
of CD34+ in C57Bl: T0: 0,7462 ± 0,2366; T24: 3,554 ± 1,001
with 𝑃 = 0,0245), (% of Sca-1+ in mdx: T0: 27,11 ± 2,053;
T24: 64,8 ± 5,408 with 𝑃 < 0,0001; T48 h: 64,95 ± 1,073
with 𝑃 < 0,0001; T4 d: 65,96 ± 3,992 with 𝑃 < 0,0001;
T7 d: 64,16 ± 1,016 with 𝑃 < 0,0001; T10 d: 62,82 ± 3,043
with 𝑃 < 0,0001. % of Sca-1+ in C57Bl: T0: 36,95 ± 4,967;
T24: 72,25 ± 2,785 with 𝑃 = 0,0003; T48 h: 62,25 ± 0,8039
with 𝑃 = 0,001; T4 d: 67,49 ± 3,772 with 𝑃 = 0,0012; T7 d:
67,3 ± 1,214 with 𝑃 = 0,0003; T10 d: 60,55 ± 1,746 with
𝑃 = 0,0021), and (% of CXCR4+ in mdx: T0: 0,4009 ±
0,1396; T24: 2,805 ± 1,091 with 𝑃 = 0,0425) (Figure 6(a)).
Furthermore, we analysed the expression of stromal cell-
derived factor 1 (SDF-1), the ligand of the CXCR4, by the
cells isolated from QA of treated and untreated mice and
we demonstrated that, after 7 days of ProAbe treatment, in
mdx mice there was a significant mobilization of SDF-1+
stem cells from bone marrow (QA of treated mdx 9,65 ± 0,25
versus QA of untreated mdx 2,5 ± 0,1; 𝑃 = 0,0014; QA
of treated C57Bl 2,25 ± 0,25 versus QA of untreated C57Bl
1,5± 0,5) (Figure 6(b)). In addition skeletal muscle frommdx
treated mice contained a higher fraction of a cell population
CD34+Sca-1+CD45+ characterized by bone marrow origin
and stemness (QA of treated mdx 0,026 ± 0,008645 versus
QA of untreated mdx 0,00323 ± 0,001862; 𝑃 = 0,0419) while
in C57Bl the two fractions were similar (Figure 6(c)). In fact a
subpopulation of cell isolated from skeletalmuscle shared few
peculiarities of bone-marrow-derived HSCs (expressing Sca-
1 and c-kit); howevermuscleHSCs donot expressCD45while
HSC derived from bone marrow express this antigen [55].
This way, the population CD34+Sca-1+CD45− representing
resident stem cell population was analyzed in QA of treated
and untreated mice and we found that it was unchanged
(Figure 6(d)).
3. Discussion
Unfortunately extensive researches were not enough to build
up efficacious strategies not only to correct the primary defect
of DMD but also to alleviate the downstream pathologies. In
the latest years, it was clear that membrane fragility caused by
the absence of dystrophin led to inflammation and fibrosis of
muscles so that several antioxidants and nutritional supple-
ments were studied to inhibit the activity of certainmolecules
(NF-𝜅B, TNF-𝛼, and TGF-𝛽) and, subsequently, to modulate
these devastating phenomena. Several works demonstrated
that, following supplementation in mdx mice, natural com-
pounds were able to reduce fibrosis [22] and to ameliorate
muscle strength [31]. Furthermore, they exerted antioxidant
activity [25] and regulated the inflammatory cells [32] and
lipid metabolism [33]. It is known that ROS could exacerbate
muscular damage by oxidizing membrane phospholipids
and proteins, thus increasing membrane permeability and
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Figure 5: Vascular features of treatedmice. (a) Panel representing staining for laminin and CD31 in QA and TA ofmdx-treated and untreated
mice. (b)The ratioCD31+ vessels/fiberwas significant only for TAofmdxmicewhile (c) the number of a-SMA+vessels/sectionwas significant
for TA of both mdx and C57Bl mice. Analysis of statistical significance was determined by unpaired t-test.
leakage [56, 57]. As expected, after ProAbe treatment, we
observed a reduction in necrotic fiber and in mononuclear
cells’ infiltration among intact fibers, together with reduced
fibrosis deposition. Furthermore small centronucleated fibers
were diminished according to a reduction of percentage of
smallest fibers and, conversely, a general increase inmuscular
mass (as shown by right-shift of frequency distribution
curve) demonstrating that an antioxidant-based diet could
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Figure 6: Stem cell mobilization driven by ProAbe. (a) Histograms representing FACS analysis of percentage of stem cell and adhesion
marker in PBMCs from treated C57Bl and mdx mice. T0 (before treatment) was used as baseline; bars represented the fold increase of
cell’s percentage relative to T0. At T24 h, both mdx and C57Bl mice showed an increase in the percentage of peripheral CD34+, Sca-1+, and
CXCR4+ cells. After 72 h of treatment the percentage of peripheral CD34+ and CXCR4+ started to decline. After 10 days of treatment the
percentage of markers analyzed was similar to T0 levels. (b) FACS analysis, showing the percentage of SDF-1+ cells in QA, was higher in both
the mice fed with ProAbe; in particular, in dystrophic mice it was more than 3-fold higher. (c) FACS analysis showing that the percentage of
CD34+Sca-1+CD45+ cells isolated fromQAwas significantly higher only in the mdx-treated mice. (d) FACS analysis showing the percentage
of CD34+Sca-1+CD45− cells isolated from treated and untreated mdx mice.
modulate muscular damage. We also demonstrated that
in treated mice there is a reduction of muscular anion
superoxide production and consequently of DNA oxidation
as observed by quantification of DHE staining, confirming
that ProAbe supplementation could influence the oxidative
state of the muscle. In addition, ProAbe could modulate ROS
production both by reducing inflammatory infiltrate or by
regulating inflammatory cells activity [58]. Skeletal muscle
mass is regulated by a balance between protein synthesis
and degradation, which is sensitive to many environmental
triggers such as mechanical load, growth factors (myostatin),
hormones (glucocorticoid), inflammatory cytokines (TNF-𝛼
and IL-6), oxidative stress (ROS and NO), metabolic stress
(ATP levels), and nutrient availability. Even if we did not
demonstrate an improvement of tetanic force in examined
muscle, we found an amelioration in endurance test in mice
fed with an antioxidant-rich diet. According to these data, it
was previously demonstrated that resistance to fatigue was
increased by a diet rich in antioxidants, probably because
of the reduction of calcium overload [45, 59]. Successively,
we tried to correlate the amelioration of endurance and
the diminished production of ROS with possible role of
mitochondrial enzymes, but we did not assess any significant
difference in the activity of these enzymes between treated
and untreated mice. On the other hand, as muscular per-
formance could depend on vascular supply to each fibre, we
demonstrated an increase in arteriolar supply by counting 𝛼-
sma+ vessels and capillaries per fibers in all treated mice.The
mechanism by which antioxidants are involved in vascular
remodelling is not completely clarified, but it is known
that polyphenols, like resveratrol, could protect NO from
inactivation favouring its biologic activities [19].
Since the work of Gussoni that firstly described the
presence of haematopoietic stem cells (HSCs) in adult skeletal
muscle [60], it was demonstrated that these cells could be
recruited according to specific molecular cues from bone
marrow tomuscle, where they actively participated inmuscle
regeneration [61]. Several papers showed that transplantation
of bone-marrow-derived HSCs in animal models of DMD
contributed not only to amelioration of skeletal muscle [62,
63] but also to endothelial cell formation [55]—probably
due to their residing perivascular niche [64]. According
to these evidences, transplantation of bone-marrow-derived
HSCs obtained preliminary but promising results in DMD
patients [65, 66]. Our data indicated an increase of the
CD34+Sca-1+CD45+ stem cells whereas the resident popula-
tion ofCD34+Sca-1+CD45− remained unchanged suggesting
a specific mobilization of bone-marrow-derived stem cells.
These cells could be involved in the amelioration of the
morphological features that we found in treated animals.
Currently, mobilized cells are also the preferable and major
source of stem and progenitor cells harvested for autologous
and allogenic transplantations because of the higher yield
of these cells, leading to faster engraftment and decreased
procedural risks compared with harvested BM cells. Even if
stem cell mobilization spontaneously takes place after tissue
damage [67, 68], several enhancers were used for clinical pur-
poses to obtain faster and significant results. It is known that
granulocyte-colony stimulating factor (G-CSF) triggers stem
cell mobilization [69] while SDF-1 attracts stem cells allowing
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their extravasation [70]. The effects of these molecules were
studied in DMD blood [71, 72], but, unfortunately, they
were associated with severe adverse effects so that they were
not feasible for human prolonged treatment [73]. However,
more recently different works described the emerging role of
natural compounds in mediating such kind of events [52–
54]. Interestingly, as we observed a mobilisation of HSCs
from bone marrow to peripheral blood in treated animals,
we suggested that ProAbe could favour the migration of
bone-marrow-derived progenitors and their participation in
muscular regeneration and endothelial formation. Similar
to the data reported by Brzoska and colleagues [74], we
showed that the augmentation of SDF-1+ stem cells was
associated with lower fibrosis rate and an improvement of
muscle regeneration. According to our results and recently
published data [75–77], we speculated that mobilized stem
cells could participate in the formation of new myofibers
while, alternatively, those cells could participate in angiogen-
esis in treated animals.
In conclusion an antioxidant-rich diet seems a promising
approach to coadjuvate therapies concerning untreatable
disease like muscular dystrophy, thanks to their ability to
improve histological and functional features of muscles and
to enhance the recruitment of stem cells. As it was shown
that combination of different polyphenols/antioxidants could
enhance their effects [17, 46–48], ProAbe could be useful
for the administration of a lower dose of each antioxidant,
thus limiting all the possible adverse events [78]. In addition,
although the precise mechanisms of action of the majority of
these compounds is not well understood, we suggested that
ProAbe could be a feasible approach in addition to standard
therapy as it can exert functional and morphological amelio-
rations in dystrophic muscles (increased CSA of myofibers,
decreased amount of inflammatory cells and necrotic fibers,
and restoration of muscle force) to counteract degeneration,
thus allowing a reduction of necessary dose of chronic drugs
and limiting their known side effects.
4. Material and Methods
4.1. Animal Ethics Statement. Procedures involving living
animals were conformed to Italian Country law (D.L.vo
116/92 and subsequent additions) and approved by local
ethics committees. This work was authorized by the National
Institute of Health and Local Committee, Protocol number
6/13-2012/2013. Three-month-old normal (C57Bl) and dys-
trophic (mdx) mice were provided by Charles River (Calco,
Lecco, Italy). The weight of C57Bl was approximately 19 g
while the weight of mdx was 25 g. Animals were caged with
comfort and safety, in controlled ambient (12-hour light, 12-
hour dark) at a temperature between 21∘Cand 24∘C: theywere
able to move freely within them and had access to clean water
and food. After one month of treatment, mice were sacrificed
by cervical dislocation according to Italian country law.
4.2. ProAbe Composition. The liquid formulation provides
DHA plus derived from purified fish oil, deodorized and
scented with lemon, and natural vitamin E. The powder
formulation provides curcumin conveyed in phytosomes,
coenzyme Q10, acetyl-L-carnitine, green tea extract, extract
of Scutellaria, and vitamin C, whose functions in modulating
dystrophic phenotype have been described above [21–23, 28,
31, 33, 34, 36, 38]. ProAbe was provided by Ystem (Milan,
Italy) in collaboration with U.G.A. Nutraceuticals (Gubbio,
Perugia, Italy).
4.3. Dosage. The recommended daily dosage for human is
1000mg of curcumin; 750mg of acetyl-L-carnitine; 200mg
of coenzyme Q10; 100mg of green tea extract; 105,3mg
of extract of Scutellaria; 1250mg of DHA; and 36mg of
vitamin E. Mice were proportionally fed (daily) with the
appropriate quantity of ProAbe (human 70 kg; mouse 20 g)
for one month for histological and endurance experiments
while formobilization experiments different time points were
considered as described in detail in the next section.
4.4. FACS Analysis of Blood-Derived Murine Cells. Periph-
eral blood (100 𝜇L) from the retroorbital sinus was taken
from each mouse and the samples were lysed to allow
cytofluorimetric studies. Blood samples were collected at
different time points: T0 (before ProAbe administration)
and T24 h, T48 h, T72 h, T4 days, T7 days, T10 days, and
T14 days following ProAbe administration. For five-colour
flow cytometry cells were incubated with 10 𝜇L primary
antibodies against CD34 FITC, SCA1 PE (BD Biosciences,
San Diego, CA, USA), CD184 (CXCR4) APC (Miltenyi
Biotech, Bologna, Italy), and CD45PE-Cy7 (eBioscience, San
Diego, CA). QA were weighed and washed several times in
PBS, finelyminced with scissors, and incubated at 37∘C for 45
minutes with 1mg/mL collagenase type IA (Sigma-Aldrich),
80 𝜇g/mL DNase I (Roche), and Trypsin 2,5% (1 : 3) (Gibco)
in Dulbecco’s modified Eagle’s medium (Invitrogen). Most of
the skeletal muscle stem cells were released from the tissue
after this step. The cell extract was filtered with a 70𝜇m
nylon mesh (BD Biosciences, Immunocytometry Systems,
Mountain View, CA) and labelled for FACS analysis. After
each incubation, performed at 4∘C for 20min, cells were
washed in PBS 1% heat-inactivated FCS and 0.1% sodium
azide. Isotype-matched immunoglobulinswere added to each
control sample. The cells were analysed using the Cytomics
FC500 and CXP 2.1 software (BC, Beckman-Coulter). Each
analysis included at least 50000–200000 events for each gate.
A light-scatter gate was set up to eliminate cell debris from
the analysis. The percentage of positive cells was assessed
after correction for the percentage reactive to an isotype
control conjugated to relative fluochromes. Bonemarrowwas
collected from treated and untreated mdx and C57Bl mice by
flushing femurs and tibias with saline solution and red blood
cells were lysed with ammonium chloride. Nucleated cells
were labelled in phosphate-buffered saline (PBS), 2% fetal calf
serum (FCS) for 45min at 4∘C with CD184 (CXCR4) APC
and SDF-1 antibody (R&D Systems). Goat anti-mouse 647
was used as secondary antibody.
4.5. Immunohistochemistry. Fromboth treated and untreated
mdx mice DIA, QA and TAmuscles were removed, frozen in
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liquid nitrogen-cooled isopentane, and sectioned on cryostat.
We performed histological analysis on QA and TA as these
muscles show similar level of dystrophic degeneration in
mdx mice. Furthermore we investigated DIA muscle as it
is the muscle that mostly recapitulates human pathology.
Serial sections of 10 𝜇m in thickness were stained with
H&E and AM. Images were captured with LEICA AS LMD
optical microscope. For immunofluorescence analysis, sec-
tions were incubated with antibodies: rabbit anti-laminin
(1 : 50; Abcam), rat anti-CD31 (1 : 100; BD), anti-𝛼 smooth
muscle actin (1 : 50 Sigma), and anti-CD11b (1 : 50, R&D).The
slides were analysed using a fluorescent microscope (LEICA
DMIRE2) and a confocal microscope (LEICA TCS-SP2).
For quantitative analysis ImageJ Software (NIH) was used.
For CD11b and DHE correlation study serial sections were
utilised.
4.6. Endurance Test and Tetanic Force. Endurance perfor-
mance test was conducted as previously described [79].
Briefly, 10micewere placed on the belt ofmotorized treadmill
(Columbus Instruments). The treadmill was run at an incli-
nation of 0∘ at 5m/min for 5min, after which the speed was
increased 1m/min every minute. The test was then stopped
when the mouse remained on the shocker plate for 20 s
without any attempt to reengage the treadmill, and the time
to exhaustion (expressed in minutes) was determined. This
test was performed daily for 30 days [80, 81]. Regarding
tetanic force measurement, the experiments were performed
as previously described [79]. Relative motor capacity was
analyzed at 4 different time points (each week for 30 days)
while time to exhaustion at T4 (30 days).
4.7. Dihydroethidium Staining for ROS Detection. Dihy-
droethidium (DHE) is a commonly used indicator of ROS
production, both in vitro [82] and in vivo [83]. DHE analysis
was performed as previously described [84]. Briefly, ROS
production was measured by incubating TA and QA cross-
sections with 5 𝜇m DHE in PBS at 37∘C for 30min. DHE
intensitywas analyzed by confocalmicroscope and quantified
by counting the number of pixels exceeding a specified
threshold, which was set in order to eliminate interference
from any background fluorescence using ImageJ software.
4.8. Mitochondria. We collected DIA and QA of mdx and
C57Bl mice fed with ProAbe and we prepared these samples
for further analysis as earlier described [85]. Mitochondrial
respiratory chain enzyme and citrate synthase activities were
measured spectrophotometrically by described assays [85].
The specific activity of each complex was normalized to that
of citrate synthase.
4.9. Statistical Analysis. Data were expressed as means ± SD.
The fibres’ counting in mdx mice was compared by Student’s
t-test. To compare multiple group means, one-way analysis
of variance (ANOVA) was used. When only two groups were
compared, the t-test was applied assuming equal variances.
The difference among groups was considered significant at
𝑃 = 0,05.
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